Abstract
Introduction
A new variant of Ebola virus (EBOV), Ebola-Makona, has been responsible for causing a large sustained viral outbreak in West Africa (2014) (2015) . During the course of the crisis several experimental therapies and vaccines have been trialled, with some success, but overall this has illustrated the long lack of development of therapeutic strategies for EBOV. EBOV has a negative sense RNA genome that is encapsidated by the virally encoded nucleoprotein (NP). The N-terminal region of NP is thought to be important for RNA binding via its interaction with the phosphodiester backbone of the RNA. 6 When the NP binds to the viral RNA genome it forms a highly stable NP-RNA complex structure (the RNP). This complex along with the viral protein 30 (VP30), the viral protein 35 (VP35) and the RNApolymerase RNA dependent (L) form the polymerase complex 7 , and these four viral proteins when expressed in cells, can replicate and transcribe EBOV RNA. This has been exploited in the development of plasmid based mini-genome systems that faithfully recapitulate EBOV RNA synthesis in the absence of infectious virus. 8 Thus opening the study of the function of the four viral proteins, viral RNA and also high throughput screening at containment level 2 (CL2). This work targeted NP to determine whether it interacted with host cell proteins, what these proteins were and how these might function in the biology of NP.
In order to comprehensively define the cellular interactome of EBOV NP a high-affinity co-immunoprecipitation coupled to a label free mass spectrometry-based approach was used. Using conservative selection criteria, approximately 150 cellular proteins were identified that had a high probability of interacting with NP. These included the heat shock protein 70 To assess the effect of inhibiting HSP70 on the synthesis of EBOV RNA, a mini-genome system was developed based on the EBOV Makona isolate, taken from the 2014-2015 West African outbreak. This mini-genome system recapitulated the essential stages of virus replication and transcription and expressed a luciferase reporter gene under the control of viral replication/transcription signals, and can be used to investigate viral genetics and screen inhibitory compounds to both viral (and cellular) proteins. 9 Perturbations to replication and/or transcription would result in alterations in the abundance and hence activity of luciferase, which can be easily assayed.
The four viral proteins essential for encapsidation of viral RNA and replication and transcription (L, VP35, VP30 and NP) were expressed as codon optimized proteins from support plasmids. The data presented in this work indicated that amount of luciferase produced by the mini-genome system decreased in cells treated with the HSP70 inhibitor compound VER-155008 compared to untreated cells, therefore the synthesis of EBOV RNA was reduced by inhibition of HSP70. These results suggest that HSP70 may play an important role for the EBOV virus replication probably by providing stability to NP.
Experimental procedures

Construction of plasmids that express EBOV NP fused to EGFP.
A codon optimized cDNA sequence for the ORF for EBOV (NCBI reference sequence number: NP_066243.1) and RESTV (NCBI reference sequence number: NP_690580.1) were cloned into the pEGFP-C1 and pEGFP-N1 plasmids to generate NP with C-terminal EGFP tag (NP-EGFP) or N-terminal EGFP tag (EGFP-NP). Once cloned, the plasmids and the insert integrity were confirmed by sequencing.
Plasmids used for the EBOV Makona mini-genome system.
The mini-genome system for EBOV (Makona strain), expressing luciferase, used in this study, was designed following the mini-genome system model developed by Mülhgerber in 1999. 8 The EBOV isolate H.sapienswt/GIN/2014/Makona-Gueckedou-C07 complete genome (NCBI sequence number KJ660347.2) sequence was used for the construction of the support plasmids. Furthermore, 50 sequences of EBOV isolates, characterised during this outbreak, were also used as a point of reference. 10 
Expression of NP and EGFP tag in HEK 293T cells.
Human embryonic kidney 293 (HEK 293T) cells were grown in Dulbecco's modified Eagle's medium (DMEM; Sigma Aldrich) supplemented with 10% fetal bovine serum (FBS; Sigma Aldrich) and 1% penicillin-streptomycin (Sigma Aldrich) at 37°C with 5% CO 2. In order to transfect HEK 293T cells, two 145cm 2 dishes were seed with 4x10 6 cells 24 hours prior to transfection.
Calcium phosphate transfection was performed with 25.6µg of plasmid DNA for each plasmid; EGFP, EGFP-NP and NP-EGFP. Cells were harvested 24 hr post transfection, lysed and co-immunoprecipitated using a GFP-Trap (Chromotek).
NP-EGFP co-immunoprecipitation
NP/EGFP fusion proteins and EGFP co-immunoprecipitations were done using a GFP-Trap_A (Chromotek) as described in previous publications. 2 Co-immunoprecipitated samples were then analysed using label free mass spectrometry. To investigate whether the interaction of NP with selected cellular proteins was mediated by RNA binding an RNAse treatment (15 units of RNAse (QIAGEN; 19101) was performed after the coimmunoprecipitations the with GFP-Trap.
Reverse co-immunoprecipitations
Reverse co-immunoprecipitations for the cellular proteins; chaperon HSP70 and its co-chaperon BAG-2 were performed using 50 l of the immobilized recombinant protein G resin (Generon) and specific antibodies against HSP70 (Abcam; ab2787) and BAG-2 (Abcam; ab47106). Reverse coimmunoprecipitation for EGFP-NP and NP-EGFP was done using an EBOV/NP Ab (IBT bioservices, 01-012); and on EGFP only as a negative control. The reverse co-immunoprecipitations were performed as described before. . 2 For western blot analysis the elution step was done in 100 l of 2xSDS-sample buffer (120mM Tris/Cl pH6.8; 20% glycerol; 4%SDS, 0.04% bromophenol blue; 10% -mercaptoethanol)
Label free Mass Spectrometry and bioinformatics analysis.
Label free proteomic analysis was performed as described previously for studying the interactome of EBOV VP24 2 , the mass spectrometry analysis was performed in triplicate for EGFP-NP, NP-EGFP and EGFP. Once label free mass spectrometry results were processed, the Perseus software 
Western blot analysis
After the co-immunoprecipitation or reverse co-immunoprecipitation, western blot was performed as described previously. Antibodies used included EBOV/NP (IBT bioservices; 0301-012), GFP (Santa Cruz Biotechnology; sc- 
Results
Expression of EBOV NP in 293T cells
To determine the cellular interacting partners of EBOV NP a high affinity EGFP co-immunoprecipitation (co-IP) coupled to a label-free mass spectrometry approach was used ( Figure 1A ). The target protein, NP, was expressed as an EGFP-fusion protein; this technique has been shown to improve the sensitivity and also to allow the discrimination between specific and non-specific interaction to the target proteins. The fusion proteins were overexpressed in cells, and proteins were extracted from lysed cells and used for co-immunoprecipitation. To identify the potential interacting partners of NP, the eluate or bound fraction was then analysed by label free mass spectrometry. To reduce the false positive rate, EGFP alone was also expressed in 293T cells as a control. The 293T cells were selected for this study due to their high efficiency for calcium phosphate mediated transfection, annotation of the human protein database and because this cell line is permissive for EBOV infection. 13; 14; 15 Protein expression was confirmed in 293T cells using immunofluorescence;
the efficiency of transfections for all plasmids was approximately 70% ( Figure 1B ). Interacting partners for NP were then co-immunoprecipitated using an EGFP-Trap. After co-immunoprecipitation, both input and elution (or bound) samples were analysed using western blot; a protein corresponding to the molecular weight of NP-EGFP (131 kDa) was detected using and anti-EGFP Ab and an anti-NP antibody ( Figure 1C ). Label free mass spectrometry and quantitative proteomics was then used to distinguish between the EBOV NP-EGFP and EBOV NP-EGFP interactomes from the control (EGFP alone), which led to the identification of possible interacting partners for NP.
Identification of the potential cellular interacting partners of EBOV NP
Potential interacting partners for NP were identified by label free mass spectrometry; a statistical analysis approach was used in order to help (Tables   2A and 2B ). The cellular proteins that were unique to each construct had generally lower fold enrichment compared to those that interacted with both constructs. One exception was the stress-induced phosphoprotein 1 (STIP1).
These unique proteins may be reflective of forming association with NP proximal to the position of the EGFP-tag, which may sterically hinder the interaction. Selected proteins with a higher probability of interacting with NP were selected for follow on studies (Tables 1A and 1B Figure   3A ).
NP is a RNA binding protein, therefore to investigate whether these interactions were protein-protein rather than protein-RNA mediated, input samples were treated with RNAse before co-immunoprecipitation ( Figure   3B ). After immunoprecipitation of the treated input samples, the bound samples were analysed again by western blot using specific antibodies against selected proteins HSP70, BAG2 and DNAJA2 ( Figure 3C ). The selected target proteins were found in the bound fraction after the RNAse treatment, which indicated that the interactions were not potentially mediated by RNA. However, DNAJA2 showed a reduction in the amount of protein in the pull down after the RNAse treatment ( Figure 3C ), indicating its interaction with NP was (part) RNA-mediated.
To further validate the mass spectrometry results and the potential interacting partners of NP, reverse co-immunoprecipitation was performed against selected cellular targets where antibody combinations allowed.
These targets were NP (as a positive control), HSP70 and BAG2. NP was overexpressed in 293T cells and then cellular proteins were extracted.
Immunoprecipitations were then performed using protein G beads and specific monoclonal antibodies against HSP70 or BAG2. The bound samples obtained from the reverse co-immunoprecipitations were then analysed by western blot, which confirmed the presence of NP ( Figure 4A ) and the interaction with HSP70 and BAG2 ( Figure 4B and 4C, respectively). As a result of these interactions we hypothesized that HSP70 and other chaperones were important for viral RNA synthesis by promoting the stability of the N protein.
Interaction with HSP70 maintains the stability of NP.
To test the hypothesis that the function of HSP70 was critical for maintaining the stability of NP, a small molecular inhibitor compound was selected that prevents the interaction of HSP70 with the target protein, 16; 17 
The stability of wild type NP is dependent on HSP70 and disruption negatively impacts viral RNA synthesis
We hypothesized that disruption of HSP70 would negatively impact wild type NP and have a concomitant effect on viral RNA synthesis. To dissect this precise function and recapitulate this safely at CL-2, a mini-genome system for EBOV was developed (based on EBOV sequence from the recent West African outbreak). This was designed following the methodology developed to study other variants of EBOV. 8 The EBOV mini-genome system used in this study consisted of four support plasmids that expressed codon optimized L, VP30, VP35 and NP with a mini-genome plasmid expressing an artificial viral genomic RNA that contained the leader and trailer sequences from EBOV with the luciferase (luc) gene as a reporter gene ( Figure 6A ).
Expression of viral mRNAs were under the control of a T7 promoter and translation of the resulting proteins facilitated by an IRES. The amount of each plasmid used for the mini-genome system to produce luciferase was optimized (Table 3) and GAPDH was compared for each treatment condition and to a control.
These were untreated cells either not expressing or expressing the L with the rest of the mini-genome components ( Figure 7A ). The activity of luciferase in these different treatment conditions was also measured ( Figure 7B ). Similar to the observations with the EGFP-tagged NPs, increasing concentrations of VER-155008 negatively impacted the abundance of native NP and also luciferase expression but had no effect on GAPDH. Also, the activity of luciferase was decreased in the mini-genome system in the presence of increasing concentrations of VER-155008. Taken together this data indicated that the stability of NP was dependent on functioning HSP70.
When NP was disrupted, synthesis of the luciferase mRNA in the minigenome system was adversely effected.
The interaction with protein chaperones is conserved in other members of the Ebola virus family.
We hypothesized that if protein chaperones are important for the biology of EBOV NP then association with these proteins would be conserved in other members of the Ebola virus family. In terms of pathogenic outcome in humans, RESTV is most different from EBOV, in that no disease has been reported in humans that have been found to been potentially infected with the virus. 7 EBOV and RESTV NPs share 68% identity at the amino acid level.
To investigate the interactome of RESTV NP, the protein was expressed in (Table S1 , S2, S3, S4).
Due to its emerging importance in viral biology as illustrated by in depth work on Dengue virus 18 , HSP70 was selected for further functional analysis using a specific small molecule inhibitor. HSP70 is involved in several cellular processes including protein folding, regulation of the stress response, and control of the activity of regulation proteins. 23 Due to its multi-functional nature, HSP70 may also play an important role in viral survival strategies 24, 25; 26 such as avoiding degradation of certain viral proteins 21; 27 , that may be expressed in large quantities or have complex folding; viral envelope protein/folding maturation 27 
Notes
The authors declare no competing financial interest. Table S1 and S2: Complete list of cellular proteins that have a higher probability of forming protein-protein interactions with EBOV/NP.
Supporting Information
Shown are candidate proteins identified using the (S1) EGFP-EBOV/NP, (S2) EBOV/NP-EGFP fusion proteins and identified using label free quantitative proteomics. Table S3 HSP70 and BAG2 were used for the reverse pull down. Then, the presence of the protein complex NP-EGFP was confirmed using western blot analysis and a specific antibody against EGFP (for reverse pull down for EBOV-NP);
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